Ex Vivo Expanded Allogeneic Mesenchymal Stem Cells Provide Durable Treatment for Fistulizing Crohn’s Disease

The results of three phase Ib/IIa clinical trials show that treatment with ex vivo expanded allogeneic bone marrow-derived mesenchymal stem cells is safe and effective for severe perianal, rectovaginal, and peripouch fistulizing Crohn’s disease. At 6 months, 83.3% of perianal, 33.3% of rectovaginal, and 30.8% of pouch fistula treatment cohorts achieved combined clinical and radiographic healing. At 12 months, 67.7% of perianal, 37.5% of rectovaginal, and 46.2% of peripouch fistulizing Crohn’s disease patients maintained complete healing.